VolitionRx Limited (VNRX) Prepays $500K, Secures Conversion Waiver

What happened

VolitionRx made a $500K cash prepayment on its January 15, 2026 senior secured convertible note to Lind, reducing the balance to $706,667. Lind agreed not to convert before January 1, 2027 unless shares close at or above $0.275, and November–December 2026 repayments are deferred.

Confirmed

Global impact / market context

Paying down debt with cash reduces the remaining amount owed and may lower interest costs. The conversion block limits new shares entering the market below $0.275, which means less dilution, or ownership shrinkage for existing holders, until that price or date is reached.

Analyst inference

This continues a deleveraging push, which means reducing borrowed money. Over $5.0M across two Lind notes was reportedly extinguished since June 30, and an earlier 2025 note was fully repaid in September, removing prior debt that can weigh on shares.

Analyst inference

What to watch

1. The remaining note balance is $706,667, so a full payoff would remove this liability. Watch whether VolitionRx prepays or repays the rest before the deferred November–December 2026 payments come due. Confirmed
2. Analysts suggest that a full payoff of the remaining note plus evidence of improving operating cash would turn this into a stronger equity catalyst, meaning a clearer reason for investors to revalue the shares. Proposed
3. Watch whether VNRX shares close at or above $0.275, because that price unlocks Lind's ability to convert the note into shares before January 1, 2027, raising dilution risk, which means ownership shrinkage, for existing holders. Analyst inference

Evidence

• Original source link unavailable